$2.93
-0.25 (-7.86%)
Open$3.16
Previous Close$3.18
Day High$3.19
Day Low$2.85
52W High$3.54
52W Low$0.99
Volume—
Avg Volume903.1K
Market Cap182.72M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+1,396.6% upside
Current
$2.93
$2.93
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 151.24M | 152.04M | 19.43M |
| Net Income | -75,485,060 | -68,298,536 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -63,742,229 | -60,877,769 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |